Meeting
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.
Authors
Neil E. Faulkner
University of Tennessee Medical Center, Knoxville, TN
Neil E. Faulkner , Tamar Melkadze , Santosh Nair , Nashat Gabrail , Gopal Kunta , Emad Ibrahim , Luke Dreisbach , Daniel Brungs , Nana Chikhladze , Miranda Gogishvili , Natalie I Vokes , Tara Hiley , Christopher Nguyen , Maria Ghattas , Siyu Li , Mark Salvati , Israel Lowy , Matthew G. Fury , Luca Paoluzzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05785767
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS8663)
DOI
10.1200/JCO.2024.42.16_suppl.TPS8663
Abstract #
TPS8663
Poster Bd #
519b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).
First Author: Michele Maio
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
First Author: Nataliya Mar